Latigo Biotherapeutics, Inc. <LTGO.O>: Leerink Partners initiates coverage with Outperform rating; target price $36
LTGO•Related News
Medtronic FY27 Q1 GAAP diluted EPS rises 40.7% to $1.14; revenue climbs 13.7% to $9.8 billion
MDT•
Cook hands Apple to Ternus: bigger and richer, but catching up in AI race
AAPL•
Crane <CR.N>: Deutsche Bank cuts target price to $240 from $248
CR•
Xenia Hotels & Resorts, Inc. Cuts to Market Perform From Outperform; Cuts Target Price to $20.5 From $22
XHR•
Chicago wheat hits 3-1/2 year top on Russia's Black Sea attacks
DBA•